USPTO Patent Applications - Peptides (C07K)

USPTO Patent Application: IL-17 Antibody Compositions

The USPTO has published a patent application (US20260083842A1) detailing pharmaceutical products and stable liquid compositions of IL-17 antibodies, such as secukinumab. The application covers methods of making these compositions and their use in treating IL-17-mediated disorders, including autoimmune conditions like psoriasis and rheumatoid arthritis.

Bispecific Molecule Stabilizing Composition Patent Application

The USPTO has published a patent application (US20260083841A1) for a pharmaceutical composition designed to stabilize bispecific antigen-binding molecules at increased concentrations. The composition includes buffer agents, saccharides, and specific stabilizing agents like EDTA or citric acid.

USPTO Patent Application: NEO-201 Antibody for Suppressing Myeloid Derived Suppressor Cells

The USPTO has published a patent application (US20260083840A1) detailing methods for ablating myeloid derived suppressor cells using the NEO-201 antibody. The application describes the antibody's specific binding to certain O-glycans and its potential use in treating cancers and infectious diseases by suppressing gMDSCs.

USPTO Patent Application: Treating NSCLC with Dostarlimab or Biosimilar

The USPTO has published a patent application detailing a method for treating non-small cell lung cancer (NSCLC) using dostarlimab or a biosimilar. The application outlines a treatment approach for patients previously treated with an immune checkpoint inhibitor.

USPTO Patent Application: Modified Coronavirus Spike Antigen Protein

The USPTO has published a patent application (US20260083836A1) for a modified coronavirus spike antigen protein. The application describes a protein designed to suppress cell membrane fusion ability and improve safety by modifying cleavage sites, aiming to enhance vaccine efficacy and antibody production.

USPTO Patent Application: Phage T4 Nanoparticle Vaccine Platform

The USPTO has published a patent application (US20260083835A1) detailing a modular bacteriophage T4 nanoparticle vaccine platform. This platform is designed for the rapid development of dual COVID-19 and flu mucosal vaccines, administered intranasally without an adjuvant.

USPTO Patent Application for CsgA-Derived Nanostructures for Antigen Delivery

The USPTO has published a patent application (US20260083834A1) for CsgA-derived nanostructures designed for antigen delivery. The application details self-assembling polypeptides conjugated to immunogens that form nanofilaments to stimulate immune responses, potentially for vaccines against various conditions.

USPTO Patent Application: Engineered Probiotics Expressing Anti-Inflammatory Molecules

The USPTO has published a patent application (US20260083783A1) from the University of Cincinnati for engineered probiotics that express anti-inflammatory molecules. The application details a genetically modified E. coli bacterium designed to produce a microbial anti-inflammatory molecule (MAM) protein.

USPTO Patent Application for Generating CD4 T Cells

The USPTO has published a patent application (US20260083778A1) for methods of generating CD4 T cells from progenitor cells. The application, assigned to Boston Medical Center Corporation, describes a specific differentiation process for therapeutic use.

USPTO Patent Application: CARs for Hidradenitis Suppurativa Treatment

The USPTO has published a patent application (US20260083777A1) filed by Sonoma Biotherapeutics, Inc. The application describes chimeric antigen receptors (CARs) designed to target citrullinated polypeptides for the treatment of hidradenitis suppurativa.

USPTO Patent Application: Cancer Treatment with Anti-CD20 Antibody and Acylfulvenes

The USPTO has published a patent application (US20260083691A1) filed by Lantern Pharma Inc. The application describes a method for treating cancer by combining an anti-CD20 antibody with acylfulvenes. This patent application is related to novel therapeutic combinations for B-cell cancers.

USPTO Patent Application: Thiazolidine Linkers for Protein-Drug Conjugates

The USPTO has published a new patent application (US20260083856A1) detailing thiazolidine linkers for protein-drug conjugates and their uses in treating diseases. The application was filed on September 11, 2025, and is scheduled for publication on March 26, 2026.

USPTO Patent Application: Anti-DPP3 Antibody Formulations

The USPTO has published a patent application from 4TEEN4 Pharmaceuticals GmbH for formulations and dosage amounts for administering an anti-DPP3 antibody or fragment thereof to humans. The application, filed on August 26, 2025, details potential treatments for life-threatening circulatory failure conditions such as shock.

USPTO Patent Application: Recombinant Human Type III Collagen for Angiogenesis

The USPTO has published a patent application (US20260083883A1) detailing recombinant human type III collagen designed to promote angiogenesis. The application describes modifications to natural type III collagen to enhance its angiogenic function and adhesion properties, potentially increasing the angiogenesis rate by over 37%.

USPTO Patent Application: Compositions Targeting Endothelial Cells

The USPTO has published a patent application from Harvard College detailing novel compositions for targeting endothelial cells. These compositions, which include binders, linkers, and radioactive isotopes, are intended for selective delivery to cells and treating diseases, including cancer.

USPTO Patent Application: Sustained Transgene Expression of Modified ERT2 Peptide Fusion

The USPTO has published a patent application (US20260083859A1) detailing a novel fusion polypeptide for sustained transgene expression. The application, filed by inventors from various institutions, describes targeting constructs for inducible cell death systems using modified estrogen receptor ligand binding domains.

USPTO Patent Application for Capsid Polypeptides

The USPTO has published a new patent application (US20260083863A1) from Dyno Therapeutics, Inc. for capsid polypeptides designed for payload delivery. The application details specific polypeptide sequences and their methods of use in therapeutic applications.

USPTO Patent Application for Immunoconjugates

The USPTO has published a new patent application, US20260083855A1, filed by Hoffmann-La Roche Inc. The application relates to immunoconjugates comprising a mutant interleukin-2 polypeptide and an antibody that binds to PD-1. This filing is part of the standard patent application process.

USPTO Patent Application: Antibody Conjugates with Bis-MSPT Linker

The USPTO has published a new patent application (US20260083854A1) detailing antibody conjugates that utilize a bis-MSPT linker. The application, filed by inventors Riazul Alam, Guillermo S. Cortez, and Yan Wang, describes pharmaceutical compositions and methods related to these conjugates.

USPTO Patent Application: CD70 Antibody Drug Conjugates

The USPTO has published a new patent application (US20260083853A1) detailing CD70 antibody drug conjugates for treating cancer and autoimmune diseases. The application was filed on October 25, 2023, by inventors Xiao Shang and others.

USPTO Patent Application for Peptoid Nucleic Acid Delivery

The USPTO has published a patent application (US20260083769A1) detailing novel hydroxyalkyl-capped cationic peptoids for nucleic acid delivery. The application, filed by inventors from various institutions, describes compositions and methods for delivering polyanionic compounds to cells and eliciting immune responses.

USPTO Patent Application: Ultrasensitive Immunoassay Method and Reagents

The USPTO has published a patent application detailing a new method and reagents for ultrasensitive detection of target molecules using reconstituted functional proteins. The invention aims to improve specificity and signal-to-noise ratios in various assay formats, including those for detecting viruses, bacteria, and proteins.

USPTO Patent Application: Pathogen Surrogates for Fresh Produce Sanitation

The USPTO has published a patent application (US20260079142A1) detailing pathogen surrogates with DNA tags for verifying sanitation systems in fresh produce processing. The application describes a method using these surrogates to mimic pathogen behavior during sanitation and subsequent DNA detection.

USPTO Patent Application for Tau Phospho Binding Antibodies

The USPTO has published a patent application (US20260079168A1) for Tau phospho binding antibodies and antigen binding fragments thereof. The application, filed on September 15, 2025, relates to methods for detecting Tau phospho (Thr217) and potential diagnostic or therapeutic uses for diseases associated with it.

USPTO Patent Application for Multivalent CLTX-CAR γδ T-cells

The USPTO has published a patent application (US20260078529A1) for multivalent CLTX-CAR γδ T-cells, which are designed for treating cancer or tumors. The application details specific T-cell compositions, pharmaceutical formulations, and methods of co-administering these cells with chemotherapeutic agents.

USPTO Patent Application: Orthogonal Mutations for Heterodimerization

The USPTO has published a patent application (US20260078202A1) detailing orthogonal mutations for heterodimerizing domains, particularly in antibody CH3 domains. This application, filed on April 25, 2025, by Jonathan Harry Davis and Nicholas M. Marshall, describes heterodimeric polypeptides and antibody constructs.